Source: Annual Congress 2006 - Pulmonary arterial hypertension: from bench back to bedside
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Montani, R. Souza, M. Wolf, O. Sitbon, G. Simonneau, M. Humbert (Clamart, France). Response of plasma von Willebrand factor to systemic endothelial injury in pulmonary arterial hypertension. Eur Respir J 2006; 28: Suppl. 50, 3149

Member's Comments

No comment yet.

Related content which might interest you: Elevated Von Willebrand Factor expression in the activated pulmonary endothelium of chronic thromboembolic pulmonary hypertension patients enhances platelet adhesion. Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Expression of CD 34 and von Willebrand factor in pulmonary endothelium Source: Eur Respir J 2001; 18: Suppl. 33, 243s Year: 2001 Microalbuminuria and von Willebrand factor antigen (vWF) as markers of endothelial dysfunction in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 123s Year: 2004 Pulmonary artery endothelial cell secretion of factor VIII Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 Endothelin, endothelial cells and von Willenbrandt factor in peripheral blood in asthma patients Source: Eur Respir J 2003; 22: Suppl. 45, 77s Year: 2003 Serum levels of vascular endothelial growth factor in patients with systemic sclerosis. Correlation with systolic pressure in the pulmonary artery Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Changes of plasma von Willebrand factor in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 138s Year: 2007 Increased platelet reactivity and thrombogenesis in pulmonary arterial hypertension subgroups Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Nerve growth factor expression and function in pulmonary arterial hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 PP308 – Endothelial injury in Chronic Obstructive Pulmonary Disease assessed by microalbuminuria (MAB) and von Willebrand factor levels and activity Source: ERS Lung Science Conference 2021 Year: 2021 Circulating angiopoietins in idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010 Endothelin-1 and coagulation parameters in pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 25s Year: 2002 Possible role of imatinib in clinical pulmonary veno-occlusive disease Source: Eur Respir J 2008; 32: 232-235 Year: 2008 Dual mechanism of platelet-derived growth factor (PDGF)-receptor: Contribution of vascular response to the pathogenesis of pulmonary hypertension (PH) Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Elevated factor FVIII:C levels in patients with pulmonary hypertension: a marked of endothelial dysfunction? Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003 P-selectin and PDGF serum levels might not be related to idiopathic pulmonary arterial hypertension and schistosomiasis Source: Annual Congress 2010 - Pulmonary circulation III Year: 2010 Expression of platelet derived-growth factor (PDGF) in remodelled pulmonary arteries of COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 25s Year: 2002 VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Pulmonary arterial hypertension in scleroderma – manifestation of systemic endothelial dysfunction Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006